middle.news
How Noxopharm and Tezcat Are Revolutionizing Sofra™ Drug Delivery for Cancer and Inflammation
8:38am on Tuesday 5th of August, 2025 AEST
•
Biotechnology
Read Story
How Noxopharm and Tezcat Are Revolutionizing Sofra™ Drug Delivery for Cancer and Inflammation
8:38am on Tuesday 5th of August, 2025 AEST
Key Points
Tezcat Biosciences demonstrates successful attachment of Sofra oligonucleotides to its delivery system
Preclinical studies reveal strong anti-inflammatory activity of Sofra payloads
Collaboration progressing to complex animal model studies
Sofra platform’s therapeutic scope expands to cancer and chronic inflammatory diseases
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE